Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Depreciation & Amortization (CF): 2015-2024

Historic Depreciation & Amortization (CF) for Axsome Therapeutics (AXSM) over the last 10 years, with Dec 2024 value amounting to $532,000.

  • Axsome Therapeutics' Depreciation & Amortization (CF) fell 8.40% to $120,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $518,000, marking a year-over-year decrease of 3.36%. This contributed to the annual value of $532,000 for FY2024, which is 15.90% up from last year.
  • As of FY2024, Axsome Therapeutics' Depreciation & Amortization (CF) stood at $532,000, which was up 15.90% from $459,000 recorded in FY2023.
  • Axsome Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $532,000 for FY2024, and its period low was $23,864 during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $459,000 (2023), whereas its average is $418,000.
  • Per our database at Business Quant, Axsome Therapeutics' Depreciation & Amortization (CF) slumped by 36.07% in 2020 and then soared by 246.05% in 2022.
  • Axsome Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $23,864 in 2020, then skyrocketed by 218.47% to $76,000 in 2021, then soared by 246.05% to $263,000 in 2022, then soared by 74.52% to $459,000 in 2023, then climbed by 15.90% to $532,000 in 2024.